{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:30:11Z","timestamp":1783661411665,"version":"3.55.0"},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100003157","name":"Myasthenia Gravis Foundation of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003157","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Muscle and Nerve"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction\/Aims<\/jats:title><jats:p>We developed a patient\u2010 and physician\u2010weighted consensus unit called the adverse event unit (AEU) that quantifies and compares adverse event (AE) burden among any group of medications in neurological patients. In this study we evaluated preliminary validity and feasibility of measuring AE burden with the AEU in myasthenia gravis (MG).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a single\u2010center, prospective, 1\u2010year, observational study of adult MG patients presenting for routine care between April 1, 2021 and March 31, 2022. The MG Activities of Daily Living (MG\u2010ADL), the 15\u2010item MG Quality of Life revised (MG\u2010QOL15r), MG\u2010Composite, and AEU scores were obtained at all visits. A priori primary feasibility metric was AEU completion rate equal to (within 3.8%, one\u2010sided 95% confidence interval [CI]) or better than MG\u2010ADL completion rate. Time to administer AEU and MG\u2010ADL\/MG\u2010QOL15r, correlation between AEU total score and MG\u2010QOL15r, and median AEU scores for each MG medication were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fifty\u2010four patients completed 67 study visits; side effects were reported at 75% of the visits. The study met the primary feasibility endpoint; AEU and MG\u2010ADL were recorded at all visits. Times to administer the AEU (median 5\u2009minutes) and MG\u2010ADL\/MG\u2010QOL15r were similar. We observed a weak correlation of 0.29 (95% CI 0.03 to 0.51, <jats:italic>P<\/jats:italic>\u2009=\u2009.032) between AEU and MG\u2010QOL15r scores. Non\u2013statistically significant differences in median AEU scores were observed among MG medications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Our data demonstrate preliminary feasibility and validity of using the AEU to measure AE burden in MG. Future studies will compare AE burden among MG treatments and evaluate clinically meaningful AEU scores in MG.<\/jats:p><\/jats:sec>","DOI":"10.1002\/mus.27966","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T13:54:00Z","timestamp":1694094840000},"page":"32-39","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Measuring treatment adverse event burden in myasthenia gravis: Single\u2010center prospective evaluation utilizing the Adverse Event Unit (AEU)"],"prefix":"10.1002","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5034-6988","authenticated-orcid":false,"given":"Michael K.","family":"Hehir","sequence":"first","affiliation":[{"name":"Department of Neurological Sciences University of Vermont College of Medicine  Burlington Vermont USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Conaway","sequence":"additional","affiliation":[{"name":"Division of Translational Research and Applied Statistics University of Virginia  Charlottesville Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avery B.","family":"St. Sauveur","sequence":"additional","affiliation":[{"name":"Department of Neurological Sciences University of Vermont College of Medicine  Burlington Vermont USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall","family":"Feb","sequence":"additional","affiliation":[{"name":"Department of Neurological Sciences University of Vermont College of Medicine  Burlington Vermont USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2651-2349","authenticated-orcid":false,"given":"Noah A.","family":"Kolb","sequence":"additional","affiliation":[{"name":"Department of Neurological Sciences University of Vermont College of Medicine  Burlington Vermont USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waqar","family":"Waheed","sequence":"additional","affiliation":[{"name":"Department of Neurological Sciences University of Vermont College of Medicine  Burlington Vermont USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan L.","family":"McNeish","sequence":"additional","affiliation":[{"name":"Departments of Physical Medicine and Rehabilitation and Neurology University of Pittsburgh Medical Center  Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Tweedy","sequence":"additional","affiliation":[{"name":"Mission Health Neurology  Asheville North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted M.","family":"Burns","sequence":"additional","affiliation":[{"name":"Department of Neurology University of Virginia  Charlottesville Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26850"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27742"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262109"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24953"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002972"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000156"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.7.1487"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25198"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21883"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181dc1b1e"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06780.x"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24769"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790"},{"key":"e_1_2_11_15_1","unstructured":"Micromedex.Prednisone pyridostigmine mycophenolate mofetil azathioprine tacrolimus rituximab IVIG plasma exchange eculizumab.http:micromedexsolutions.comAccessed January 3 2021."},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010574"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000002864"},{"key":"e_1_2_11_18_1","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu T","year":"2022","journal-title":"N Engl J Med Evid."},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23330"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1"}],"container-title":["Muscle &amp; Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.27966","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T04:17:16Z","timestamp":1704946636000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.27966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1002\/mus.27966"],"URL":"https:\/\/doi.org\/10.1002\/mus.27966","archive":["Portico"],"relation":{},"ISSN":["0148-639X","1097-4598"],"issn-type":[{"value":"0148-639X","type":"print"},{"value":"1097-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,7]]},"assertion":[{"value":"2023-02-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}